StreetInsider.com News Articles

Vaxcyte (PCVX) PT Set at $120 at Cantor Fitzgerald - Pressure on Shares Explained by Challenging Market

Mon, 12 Oct 2026 07:10:57 -0400

Cantor Fitzgerald analyst Carter Gould set the price target on Vaxcyte (NASDAQ: PCVX) to $120.00 from NA while maintaining an Overweight rating.

The analyst commented, "Following the recent OPUS-1 top-line and the subsequent financing, we are (1) updating our model to reflect changes to our adult POS assumptions (details below) and (2) instituting a $120 price target (previously we did not assign a formal price target, though our valuation work suggested an equity value of $97/sh). Challenging market conditions coupled with typical financing pressure and the near-term catalyst path (potentially eight months to value inflecting pediatric phase 2 data) explain most

Vaxcyte (PCVX) PT Set at $120 at Cantor Fitzgerald - Pressure on Shares Explained by Challenging Market

Mon, 12 Oct 2026 07:10:57 -0400

Cantor Fitzgerald analyst Carter Gould set the price target on Vaxcyte (NASDAQ: PCVX) to $120.00 from NA while maintaining an Overweight rating.

Form 8-K Vaxcyte, Inc. For: Oct 06

Fri, 09 Oct 2026 16:42:00 -0400

si-local-file:///var/storage/secattach/20261009/27172004.html

Vaxcyte closes $1.15B public offering of stock and notes

Fri, 09 Oct 2026 16:05:15 -0400

Vaxcyte, Inc. (Nasdaq: PCVX) closed concurrent public offerings totaling approximately $1.15 billion in gross proceeds, the clinical-stage vaccine company announced Oct. 9, 2026.

The offerings comprised 8,584,375 shares of common stock priced at $64.00 per share, pre-funded warrants to purchase 400,000 shares at $63.999 per warrant, and $575 million in aggregate principal of 1.50% convertible senior notes due 2032. Underwriters exercised their options in full, adding 1,171,875 shares and $75 million in additional notes to cover over-allotments.

Vaxcyte said it intends to use the net proceeds primarily to fund clinical development of its VAX-31 pneumococcal conjugate vaccine candidate, which is currently in

Vaxcyte Announces Closing of $1.15 Billion Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes, Including Full Exercise of Underwriters’ Options to Purchase Additional

Fri, 09 Oct 2026 16:05:00 -0400

SAN CARLOS, Calif., Oct. 09, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today the closing of its previously announced concurrent underwritten public offerings of 8,584,375 shares of common stock at a public offering price of $64.00 per share, pre-funded warrants to purchase 400,000 shares of common stock at a public offering price of $63.999 per pre-funded warrant and $575 million aggregate principal amount of 1.50% convertible senior notes due 2032 (the “notes”). These offerings included the exercise in full by the underwriters of their option to purchase up to 1,171,875 additional

Vaxcyte Announces Closing of $1.15 Billion Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes, Including Full Exercise of Underwriters’ Options to Purchase Additional

Fri, 09 Oct 2026 16:05:00 -0400

Form 424B5 Vaxcyte, Inc.

Thu, 08 Oct 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20261008/27167401.html

Form 424B5 Vaxcyte, Inc.

Thu, 08 Oct 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20261008/27167371.html

Form 4 Vaxcyte, Inc. For: Oct 05 Filed by: Wassil Jim

Wed, 07 Oct 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20261007/27161319.html

Form 4 Vaxcyte, Inc. For: Oct 05 Filed by: Cowan Elvia

Wed, 07 Oct 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20261007/27161311.html

Form FWP Vaxcyte, Inc. Filed by: Vaxcyte, Inc.

Wed, 07 Oct 2026 06:05:00 -0400

si-local-file:///var/storage/secattach/20261007/27157536.html

Vaxcyte prices $1B in stock and note offerings

Tue, 06 Oct 2026 22:48:54 -0400

Vaxcyte, Inc. (Nasdaq: PCVX) announced the pricing of concurrent public offerings totaling approximately $1 billion, comprising shares of common stock, pre-funded warrants, and convertible senior notes, according to a company statement.

The clinical-stage vaccine company priced 7,412,500 shares of common stock at $64.00 per share and pre-funded warrants to purchase 400,000 shares at $63.999 per warrant. Separately, Vaxcyte priced $500 million in aggregate principal amount of 1.50% convertible senior notes due 2032. Combined gross proceeds from both offerings are expected to reach approximately $1 billion before underwriting discounts, commissions, and other expenses.

Underwriters have a 30-day option to purchase up to an

Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes

Tue, 06 Oct 2026 22:48:00 -0400

SAN CARLOS, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today the pricing of concurrent underwritten public offerings of 7,412,500 shares of common stock, pre-funded warrants to purchase 400,000 shares of common stock and $500 million aggregate principal amount of 1.50% convertible senior notes due 2032 (the “notes”). The shares of common stock are being sold at a public offering price of $64.00 per share, and the pre-funded warrants are being sold at a public offering price of $63.999 per pre-funded warrant. The exercise price of the pre-funded warrants

Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes

Tue, 06 Oct 2026 22:48:00 -0400

Vaxcyte (PCVX) PT Raised to $146 at BofA Securities

Tue, 06 Oct 2026 06:08:02 -0400

BofA Securities analyst Jason Gerberry raised the price target on Vaxcyte (NASDAQ: PCVX) to $146.00 (from $130.00) while maintaining a Buy rating.

The analyst comments "Following PCVX’s investor call, we raise our PO to $146/shr from $130/shr. The focus of the call centered on the context for the OPUS-1 results, key regulatory and competitive considerations, and implications for VAX-31’s commercial strategy. With Opus-1 delivering a clean win on the primary endpoint, few data-related questions remain. We believe the results support a broad 31-serotype label and provide a strong foundation for the planned adult BLA. Mgmt indicated that regulators may focus on

Vaxcyte (PCVX) PT Raised to $146 at BofA Securities

Tue, 06 Oct 2026 06:08:02 -0400

BofA Securities analyst Jason Gerberry raised the price target on Vaxcyte (NASDAQ: PCVX) to $146.00 (from $130.00) while maintaining a Buy rating.

Form 424B5 Vaxcyte, Inc.

Tue, 06 Oct 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20261006/27151319.html

Form 424B5 Vaxcyte, Inc.

Tue, 06 Oct 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20261006/27151320.html

Form 305B2 Vaxcyte, Inc.

Tue, 06 Oct 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20261006/27151322.html

Vaxcyte launches $1B in dual public offerings of stock and notes

Mon, 05 Oct 2026 16:28:14 -0400

Vaxcyte, Inc. (Nasdaq: PCVX) announced the commencement of two separate underwritten public offerings: $500 million in common stock and pre-funded warrants, and $500 million in convertible senior notes due 2032.

The company has granted underwriters a 30-day option to purchase up to an additional $75 million in common stock and up to $75 million in additional notes to cover over-allotments. The two offerings are independent of each other and are subject to market conditions, with no assurance provided on completion, size, or final terms.

The convertible senior notes will be senior, unsecured obligations maturing on October 15, 2032, with interest paid semi-annually.

Vaxcyte Announces Commencement of Proposed Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes

Mon, 05 Oct 2026 16:28:01 -0400

SAN CARLOS, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that it has commenced underwritten public offerings of $500 million of its common stock and pre-funded warrants and $500 million aggregate principal amount of convertible senior notes due 2032 (the “notes”) in separate public offerings registered under the Securities Act of 1933, as amended. All shares of common stock, pre-funded warrants and notes to be sold in the offerings will be offered by Vaxcyte. Vaxcyte intends to grant the underwriters a 30-day option to purchase up to an

Vaxcyte Announces Commencement of Proposed Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes

Mon, 05 Oct 2026 16:28:01 -0400

Form 144 Vaxcyte, Inc. Filed by: Cowan Elvia

Mon, 05 Oct 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20261005/27148876.html

Form 144 Vaxcyte, Inc. Filed by: Wassil Jim

Mon, 05 Oct 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20261005/27148856.html

BTIG Reiterates Buy Rating on Vaxcyte (PCVX)

Mon, 05 Oct 2026 13:38:48 -0400

BTIG analyst Tom Shrader reiterated a Buy rating and $89.00 price target on Vaxcyte (NASDAQ: PCVX).

The analyst comments "Great data and better than management's detailed predictions. By the historical bar for non-inferiority (LBCI>0.50) every serotype available in other vaccines (PCV20 and PCV21) is covered by VAX-31. The attempt to raise the bar for future technologies by raising the non-inferiority hurdle to LBCI>0.667 (approximately no worse than 67% of other vaccines) looked nearly as successful, as all 20 of 20 comparisons with PCV20 met this hurdle while 17 of 19 comparisons to PCV21 met it as well (Exhibit 1). In detail,